The debate on influencing doctors' decisions: Are drug characteristics the missing link?

Management Science

Volumn 53, Issue 11, 2007, Pages 1688-1701

  Venkataraman, Sriram ^a   Stremersch, Stefan ^b,c  

^a EMORY UNIVERSITY   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c DUKE UNIVERSITY   (United States)

Author keywords

Detailing; Drug effectiveness; Drug prescription; Marketing effort; Patient request; Pharmaceuticals; Physician decision making; Public policy; Sample dispensing; Sampling; Side effect

Indexed keywords

DRUG EFFECTIVENESS; DRUG PRESCRIPTION; PATIENT REQUEST; SAMPLE DISPENSING;

DATA STRUCTURES; DRUG PRODUCTS PLANTS; MARKETING; PATIENT TREATMENT; PUBLIC POLICY;

DECISION MAKING;

EID: 38549136076     PISSN: 00251909     EISSN: 15265501     Source Type: Journal    
DOI: 10.1287/mnsc.1070.0718     Document Type: Article

References (38)

1. Azoulay, P. 2002. Do pharmaceutical sales respond to scientific evidence? J. Econom. Management Strategy 11(4) 551-594.
2. Becker, G., K. Murphy. 1993. A simple theory of advertising as a good or bad. Quart. J. Econom. 108(4) 941-963.
3. Berndt, E. R., L. T. Bui, D. H. Reiley, G. L. Urban. 1995. Information, marketing and pricing in the U.S. anti-ulcer drug market. Amer. Econom. Rev. 85(2) 100-105.
4. Calabro, S. 2003. In DTC-free Europe, just as many patients ask for brand drugs. Medical Marketing Media 38(11) 30.
5. Chew, L. D., T. S. O'Young, T. K. Hazlet, K. A. Bradley, C. Maynard, D. S. Lessler. 2000. A physician survey of the effect of drug sample availability on physicians' behavior. J. General Internal Medicine 15(July) 478-483.
6. Chintagunta, P. K., R. Desiraju. 2005. Strategic pricing and detailing behavior in international markets. Marketing Sci. 24(1) 67-80.
7. Dong, X., P. Manchanda, P. K. Chintagunta. 2005. Quantifying the benefits of individual level targeting in the presence of firm strategic behavior. Working paper, University of Chicago, Chicago, IL.
8. Duffy, C. M., M. Clark, J. Hiris. 2003. Who receives free sample medications? J. General Internal Medicine 18(April) 205.
9. Economist, The. 2005. Survey: Devil in the detail. (June 18) 9.
10. Edwards, J. 2005. News analysis: Turf war escalates over big pharma marketing. Brandweek 46(40) 6.
11. Franses, P. H. 2005. On the use of econometric models for policy simulation in marketing. J. Marketing Res. 42(1) 4-14.
12. Gönül, F F., F Carter, E. Petrova, K. Srinivasan. 2001. Promotion of prescription drugs and its impact on physicians' choice behavior. J. Marketing 65(3) 79-90.
13. Grossman, G., C. Shapiro. 1984. Informative advertising with differentiated products. Rev. Econom. Stud. 51(1) 63-81.
14. Hradecky, G. 2004. Backlash against the number of reps in the field could change the sales model forever. Pharmaceutical Representative (April 1).
15. Hollon, M. F. 2005. Direct-to-consumer advertising: A haphazard approach to health promotion. J. Amer. Medical Assoc. 293(16) 2030-2032.
16. Janakiraman, R., S. Dutta, C. Sismeiro, P. Stern. 2005. Are they all the same? Physicians' persistence and its implications for marketing communication. Working paper, University of Southern California, Los Angeles, CA.
17. Kravitz, R. L., R. A. Bell, R. Azari, S. Kelly-Reif, E. Krupat, D. H. Thom. 2003. Direct observation of requests for clinical services in office practice: What do patients want and do they get it? Arch. Internal Medicine 163(14) 1673-1681.
18. Kravitz, R. L., R. M. Epstein, M. D. Feldman, C. E. Franz, R. Azari, M. S. Wilkes, L. Hinton, P. Franks. 2005. Influence of patients' requests for direct-to-consumer advertised antidepressants. J. Amer. Medical Assoc. 293(16) 1995-2002.
19. Leeflang, P., J. Wieringa, D. Wittink, 2004. The effects of pharmaceutical marketing on sales of prescription drugs in the Netherlands. Sixth CU-Boulder Invitational Choice Sympos., Estes Park, CO.
20. Leffler, K. B. 1981. Persuasion or information? The economics of prescription drug advertising. J. Law Econom. 24(1) 45-74.
21. Lyles, Alan. 2002. Direct marketing of pharmaceuticals to consumers. Ann. Rev. Public Health 23 73-91.
22. Manchanda, P., P. K. Chintagunta. 2004. Responsiveness of physician prescription behavior to salesforce effort: An individual level analysis. Marketing Lett. 15(2-3) 129-145.
23. Manchanda, P., P. E. Rossi, P. K. Chintagunta. 2004. Response modeling with nonrandom marketing-mix variables. J. Marketing Res. 41(November) 467-478.
24. Mintzes, B., M. L. Barer, R. L. Kravitz, B. Bassett, J. Lexchin, A. Kazanjian, R. G. Evans, R. Pan, S. A. Marion. 2003. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Canadian Medical Association J. 169(5) 405-412.
25. Mizik, N., R. Jacobson. 2004. Are physicians "easy marks?" Quantifying the effects of detailing and sampling on new prescriptions. Management Sci. 50(12) 1704-1715.
26. Morelli, D., M. R. Koenigsberg. 1992. Sample medication dispensing in a residency practice. J. Family Practice 34(1) 42-48.
27. Narayanan, S., P. Manchanda. 2004. Heterogeneous learning and the targeting of marketing communication for new products. Working paper, Graduate School of Business, Stanford University, Stanford, CA.
28. Narayanan, S., P. Manchanda. 2006. The role of free samples in the pharmaceutical industry: An empirical analysis. 2006 INFORMS Marketing Sci. Conf., University of Pittsburgh, Pittsburgh, PA.
29. Narayanan, S., R. Desiraju, P. K. Chintagunta. 2004. Return on investment implications for pharmaceutical promotional expenditures: The role of marketing-mix interactions. J. Marketing 68(4) 90-105.
30. Narayanan, S., P. Manchanda, P. K. Chintagunta. 2005. Temporal differences in the role of marketing communication in new product categories. J. Marketing Res. 42(3) 278-290.
31. Neslin, S. 2001. Analysis of ROI for pharmaceutical promotion. Unpublished study conducted for the Association of Medical Publications, http://www.rxpromoroi.org/arpp/index.html.
32. Parsons, L. J., P. Vanden Abeele. 1981. Analysis of sales call effectiveness. J. Marketing Res. 18(1) 107-113.
33. Rizzo, J. A. 1999. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. J. Law Econom. 42(1) 89-116.
34. Rosenthal, M. B., E. R. Berndt, J. M. Donohue, A. M. Epstein, R. G. Frank. 2003. Demand effects of recent changes in prescription drug information. D. M. Cutler, A. M. Garber, eds. Frontiers in Health Policy Research, Vol. 6. MIT Press, Cambridge, MA, 1-26.
35. Tanner, M. A., W. H. Wong. 1987. The calculation of posterior distributions by data augmentation. J. Amer. Statist. Assoc. 82(398) 528-549.
36. Wall Street Journal, The. 2006. Merck withheld Vioxx safety information, plaintiff's lawyer claims. (March 7) D4.
37. Weissman, J. S., D. Blumenthal, A. J. Silk, M. Newman, K. Zapert, R. Leitman, S. Feibelmann. 2004. Physician report on patient encounters involving direct-to-consumer advertising. Health Affairs (April 28) W4/219-W4/233.
38. Wilkes, M. S., R. A. Bell, R. L. Kravitz. 2000. Direct-to-consumer prescription drug advertising: Trends, impact and implications. Health Affairs 19(2) 110-128.